Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10880258rdf:typepubmed:Citationlld:pubmed
pubmed-article:10880258lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C0021666lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C1333891lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C1551336lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C0077063lld:lifeskim
pubmed-article:10880258lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:10880258pubmed:issue7lld:pubmed
pubmed-article:10880258pubmed:dateCreated2000-9-8lld:pubmed
pubmed-article:10880258pubmed:abstractTextHistone deacetylases play key roles in the regulation of gene transcription. Studies have shown that expression of interleukins IL-2 and IL-8, and insulin-like growth factor 2 (IGF2) are affected by treatment with histone deacetylase inhibitors. We have previously shown that the gene for histone deacetylase 1 (HDAC1) is upregulated following treatment with TSA. The murine homologue of this gene has been reported to be inducible by IL-2. In this study, we have examined the effects IL-2, IGF-II and TSA have on HDAC1 expression in the human hepatocellular carcinoma derived cell line Hep3B. Our results indicate that in contrast to the mouse, HDAC1 is not inducible by IL-2. However, in TSA treated cells, IL-2 and IGF-II were found to act synergistically to reduce TSA induced HDAC1 mRNA levels almost to normal.lld:pubmed
pubmed-article:10880258pubmed:languageenglld:pubmed
pubmed-article:10880258pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:citationSubsetIMlld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10880258pubmed:statusMEDLINElld:pubmed
pubmed-article:10880258pubmed:monthJullld:pubmed
pubmed-article:10880258pubmed:issn1043-4666lld:pubmed
pubmed-article:10880258pubmed:authorpubmed-author:HartmannWWlld:pubmed
pubmed-article:10880258pubmed:authorpubmed-author:O'ConnorLLlld:pubmed
pubmed-article:10880258pubmed:authorpubmed-author:EkströmT JTJlld:pubmed
pubmed-article:10880258pubmed:authorpubmed-author:Aguilar-Sante...lld:pubmed
pubmed-article:10880258pubmed:authorpubmed-author:GrayS GSGlld:pubmed
pubmed-article:10880258pubmed:authorpubmed-author:SvechnikovaIIlld:pubmed
pubmed-article:10880258pubmed:copyrightInfoCopyright 2000 Academic Press.lld:pubmed
pubmed-article:10880258pubmed:issnTypePrintlld:pubmed
pubmed-article:10880258pubmed:volume12lld:pubmed
pubmed-article:10880258pubmed:ownerNLMlld:pubmed
pubmed-article:10880258pubmed:authorsCompleteYlld:pubmed
pubmed-article:10880258pubmed:pagination1104-9lld:pubmed
pubmed-article:10880258pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:meshHeadingpubmed-meshheading:10880258...lld:pubmed
pubmed-article:10880258pubmed:year2000lld:pubmed
pubmed-article:10880258pubmed:articleTitleIGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin a.lld:pubmed
pubmed-article:10880258pubmed:affiliationLaboratory for Molecular Development and Tumour Biology, Karolinska Institute CMM, L8 01, Stockholm, Sweden.lld:pubmed
pubmed-article:10880258pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10880258pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed